Evolutionary Genomics, Inc. (FNAM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evolutionary Genomics, Inc. (FNAM) with AI Score 48/100 (Weak). Evolutionary Genomics, Inc. specializes in identifying positively selected genes for enhancing agricultural traits. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Evolutionary Genomics, Inc. (FNAM) Healthcare & Pipeline Overview
Evolutionary Genomics, Inc. is a biotechnology firm focused on gene research and identification, utilizing its Adapted Traits Platform to enhance agricultural productivity through genetic insights, positioning itself as a key player in the intersection of agriculture and genomics.
Investment Thesis
Evolutionary Genomics, Inc. presents a unique investment thesis driven by its proprietary Adapted Traits Platform, which is poised to capitalize on the growing demand for genetically enhanced crops. The global biotechnology market is projected to reach $727.1 billion by 2025, with agricultural biotechnology being a significant contributor to this growth. The company's focus on enhancing crop traits aligns with industry trends towards sustainability and food security, potentially driving revenue growth as it expands its client base among governmental and commercial entities. However, the company faces risks associated with its small size and limited resources, which could impact its ability to scale operations and compete effectively. The absence of a dividend and a negative P/E ratio further highlights the need for careful consideration of its financial health and market position.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.00B indicates a nascent stage of growth with potential for future development.
- P/E Ratio: -0.00 reflects current financial challenges, emphasizing the need for strategic growth.
- Beta: -0.14 suggests low volatility compared to the market, indicating stability in uncertain times.
- Employee count: 2, highlighting a lean operational structure focused on niche research.
- No dividend yield, which aligns with the company's reinvestment strategy for growth.
Competitors & Peers
Strengths
- Innovative Adapted Traits Platform for genetic research.
- Strong focus on sustainability and food security.
- Niche expertise in agricultural biotechnology.
Weaknesses
- Limited resources with only two employees.
- Negative P/E ratio indicating financial challenges.
- Dependence on external funding for research initiatives.
Catalysts
- Upcoming: Potential partnerships with governmental organizations to enhance research funding.
- Ongoing: Development of the Adapted Traits Platform to attract commercial clients.
- Upcoming: Expansion into international markets to tap into new agricultural needs.
Risks
- Potential: Regulatory challenges that could delay research and product development.
- Ongoing: Financial instability due to negative P/E ratio and limited resources.
- Potential: Competition from larger biotechnology firms with more resources.
Growth Opportunities
- Growth opportunity 1: The global agricultural biotechnology market is projected to reach $49.5 billion by 2025, driven by increasing demand for genetically modified crops. Evolutionary Genomics can capitalize on this trend through its Adapted Traits Platform, offering tailored solutions for enhancing crop resilience and yield.
- Growth opportunity 2: With the rising emphasis on sustainable agricultural practices, Evolutionary Genomics can expand its research initiatives to include gene editing technologies like CRISPR. This could enhance its product offerings and attract collaborations with larger agricultural firms looking for innovative solutions.
- Growth opportunity 3: The increasing investment in agricultural research from governmental and non-profit organizations provides a significant opportunity for Evolutionary Genomics to secure funding and partnerships. By aligning its research goals with these entities, the company can enhance its visibility and market reach.
- Growth opportunity 4: The ongoing global food security crisis presents an urgent need for advancements in crop genetics. Evolutionary Genomics can position itself as a leader in developing traits that improve crop resilience against climate variability, thereby tapping into a critical market need.
- Growth opportunity 5: Expansion into international markets, particularly in developing regions where agricultural innovation is crucial, can provide Evolutionary Genomics with new revenue streams. By adapting its technology to local agricultural challenges, the company can enhance its global footprint.
Opportunities
- Growing global market for agricultural biotechnology.
- Potential partnerships with governmental and non-profit organizations.
- Expansion into international markets with agricultural needs.
Threats
- Intense competition from larger biotechnology firms.
- Regulatory challenges in genetic research and modification.
- Market volatility impacting funding and investment.
Competitive Advantages
- Proprietary Adapted Traits Platform providing a unique technological advantage.
- Focus on niche market of positively selected genes, reducing direct competition.
- Expertise in agricultural biotechnology enhances credibility and attractiveness to partners.
About FNAM
Founded in 1990 and headquartered in Castle Rock, Colorado, Evolutionary Genomics, Inc. is a biotechnology company dedicated to the research and identification of positively selected genes across humans, animals, and commercial crops. The company has developed the Adapted Traits Platform, a sophisticated technology designed to pinpoint genes that can enhance various crop traits including yield, sugar content, biomass, drought tolerance, and resistance to pests and diseases. This platform not only serves agricultural needs but also caters to governmental organizations and non-profit foundations, reflecting its commitment to advancing agricultural science and sustainability. With a small team of just two employees, Evolutionary Genomics operates in a niche market, focusing on the intersection of genomics and agriculture. The company’s innovative approach positions it uniquely within the biotechnology sector, as it seeks to leverage genetic advancements to meet the growing global demand for food security and sustainable agricultural practices. Its research initiatives are essential in addressing the challenges posed by climate change and population growth, making its contributions vital for future agricultural developments.
What They Do
- Research and identify positively selected genes in humans, animals, and commercial crops.
- Develop the Adapted Traits Platform for enhancing crop traits.
- Focus on traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance.
- Serve governmental organizations, non-profit foundations, and commercial entities.
- Contribute to advancements in agricultural biotechnology and sustainability.
Business Model
- Generate revenue through research contracts with governmental and non-profit organizations.
- Collaborate with commercial entities to develop tailored genetic solutions.
- Leverage proprietary technology to enhance agricultural productivity and sustainability.
Industry Context
The biotechnology industry, particularly in the agricultural sector, is experiencing significant growth driven by advancements in genetic research and increasing demands for sustainable farming practices. As global populations rise and climate change impacts agricultural productivity, companies like Evolutionary Genomics are positioned to offer innovative solutions through genetic enhancement of crops. The market for agricultural biotechnology is expected to grow at a CAGR of 10.5% from 2020 to 2025, indicating a robust competitive landscape where Evolutionary Genomics can leverage its unique technology to gain market share.
Key Customers
- Governmental organizations seeking advancements in agricultural research.
- Non-profit foundations focused on food security and sustainability.
- Commercial entities in the agriculture sector looking for genetic enhancements.
Financials
Chart & Info
Evolutionary Genomics, Inc. (FNAM) stock price: Price data unavailable
Latest News
No recent news available for FNAM.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FNAM.
Price Targets
Wall Street price target analysis for FNAM.
MoonshotScore
What does this score mean?
The MoonshotScore rates FNAM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Steve Warnecke
CEO
Steve Warnecke has led Evolutionary Genomics, Inc. since its inception in 1990. With a background in biotechnology and genetics, he has been instrumental in establishing the company's research focus and developing its proprietary technologies. His leadership is marked by a commitment to advancing agricultural science through innovative genetic solutions.
Track Record: Under Steve's leadership, Evolutionary Genomics has developed its Adapted Traits Platform, positioning the company as a key player in agricultural biotechnology. His strategic decisions have led to collaborations with various governmental and non-profit organizations, enhancing the company's visibility in the sector.
FNAM OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements of the major exchanges like NYSE or NASDAQ. These companies may have less liquidity and less stringent reporting requirements, making them riskier investments.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may hinder investor confidence.
- Low trading volume can lead to higher volatility and difficulty in executing trades.
- Regulatory risks associated with biotechnology research and product development.
- Verify the company's financial health and operational metrics.
- Assess the competitive landscape and market positioning.
- Review any partnerships or collaborations that enhance its market reach.
- Investigate the regulatory environment affecting its research and products.
- Confirm the credibility of the management team and their track record.
- Established in 1990, indicating a long-standing presence in the industry.
- Focus on research and partnerships with governmental and non-profit organizations.
- Development of proprietary technology in agricultural biotechnology.
FNAM Healthcare Stock FAQ
What does Evolutionary Genomics, Inc. do?
Evolutionary Genomics, Inc. focuses on the research and identification of positively selected genes in various organisms, including humans, animals, and crops. The company has developed the Adapted Traits Platform, which aims to enhance agricultural traits such as yield, drought tolerance, and disease resistance, catering to governmental and commercial entities.
What do analysts say about FNAM stock?
Analyst consensus on FNAM stock is currently limited due to its OTC status and lack of comprehensive financial disclosures. However, the company's focus on agricultural biotechnology and its proprietary Adapted Traits Platform are seen as potential growth drivers, especially in light of increasing global demand for sustainable agricultural solutions.
What are the main risks for FNAM?
The primary risks for Evolutionary Genomics, Inc. include regulatory challenges that could impact its research and product development timelines, financial instability stemming from its negative P/E ratio and limited resources, and ongoing competition from larger biotechnology firms that may have more robust operational capabilities and funding.
What are the key factors to evaluate for FNAM?
Evolutionary Genomics, Inc. (FNAM) currently holds an AI score of 48/100, indicating low score. Key strength: Innovative Adapted Traits Platform for genetic research.. Primary risk to monitor: Potential: Regulatory challenges that could delay research and product development.. This is not financial advice.
How frequently does FNAM data refresh on this page?
FNAM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FNAM's recent stock price performance?
Recent price movement in Evolutionary Genomics, Inc. (FNAM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative Adapted Traits Platform for genetic research.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FNAM overvalued or undervalued right now?
Determining whether Evolutionary Genomics, Inc. (FNAM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FNAM?
Before investing in Evolutionary Genomics, Inc. (FNAM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.